Ibrexafungerp + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Candida Vulvovaginitis
Conditions
Candida Vulvovaginitis
Trial Timeline
Jan 4, 2019 → Sep 4, 2019
NCT ID
NCT03734991About Ibrexafungerp + Placebo
Ibrexafungerp + Placebo is a phase 3 stage product being developed by Scynexis for Candida Vulvovaginitis. The current trial status is completed. This product is registered under clinical trial identifier NCT03734991. Target conditions include Candida Vulvovaginitis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03987620 | Phase 3 | Completed |
| NCT03734991 | Phase 3 | Completed |
Competing Products
8 competing products in Candida Vulvovaginitis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Micafungin | Astellas Pharma | Phase 1 | 33 |
| SHR3680 + Placebo | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| Efalizumab | Merck | Approved | 85 |
| AMO959 + Enzalutamide + Abiraterone | Novartis | Phase 1/2 | 41 |
| Clotrimazole 1% (Empecid L Cream, BAYB5097) | Bayer | Pre-clinical | 20 |
| Fluconazole + SCY-078 | Scynexis | Phase 2 | 44 |
| Ibrexafungerp + Placebo | Scynexis | Phase 3 | 69 |
| hLF1-11 + hLF1-11 + Placebo | AM-Pharma | Phase 1/2 | 33 |